NCT01527539已完成3 期
A Multi-centre, Non-comparative, Open-labelled, Extension Trial to Assess the Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes (Extension to BIAsp-1237)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- HbA1c
研究概览
简要总结
This trial is conducted in North America. The aim of this trial is asses the long term safety and efficacy of biphasic insulin aspart 30 in Canadian subjects with type 2 diabetes who had participated in the BIAsp-1237 trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Completed the BIAsp-1237 trial
排除标准
- 未提供
研究组 & 干预措施
BIAsp 30
Experimental
干预措施: biphasic insulin aspart 30 (Drug)
结局指标
主要结局
HbA1c
次要结局
- Occurrence of adverse events
- Occurence of hypoglycaemic episodes
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT01467375Novo Nordisk A/S89
已完成
4 期
Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major SurgeryCongenital Bleeding DisorderHaemophilia A With InhibitorsHaemophilia B With InhibitorsNCT01561391Novo Nordisk A/S36
已完成
4 期
Novofine Autocover Safety Needle Versus BD Safety GlideHealthcare ProfessionalsDelivery SystemsDiabetesNCT00121355Novo Nordisk A/S83
已完成
3 期
Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in DiabeticsDelivery SystemsDiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2NCT00773279Novo Nordisk A/S242
已完成
4 期
NovoLog Observation Trial in Subjects With Type 1 and Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1NCT00095446Novo Nordisk A/S513